The expert panel provides comprehensive insights on another patient case, a 77-year-old with MDS who presented with symptomatic anemia.
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival
Revisit the OncLive On Air Episodes From February 2024
Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD
FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer